Michael Christie
Overview
Explore the profile of Michael Christie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
3819
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Christie M, Avenant T, Nembudani M, Mnqandi A, Muller C, de Villiers M, et al.
BMC Infect Dis
. 2025 Mar;
25(1):362.
PMID: 40087547
Introduction: Bloodstream infections (BSIs) significantly contribute to the morbidity and mortality in paediatric burn patients from low- and middle-income countries; with common pathogens like Staphylococcus aureus, Escherichia coli, and Pseudomonas...
2.
Dissanayake H, Guruwiwi G, Gurruwiwi G, Dhurrkay J, Tynan J, Braat S, et al.
Med J Aust
. 2025 Jan;
222(4):183-190.
PMID: 39888043
Objective: To evaluate the impact of a 4-month dietary and lifestyle program co-designed and led by Aboriginal and Torres Strait Islander people on weight and metabolic markers, diet, and physical...
3.
Clark M, Christie M, Jones M, Ashley S, Tang M
Photochem Photobiol Sci
. 2024 Dec;
24(1):23-35.
PMID: 39648192
Higher prevalence of multiple sclerosis at higher latitudes is associated with reduced sunlight during childhood. Alterations in inflammatory Th17 and regulatory T cells (Treg) are associated with autoimmunity. In Hobart,...
4.
An immune suppressive tumor microenvironment in primary prostate cancer promotes tumor immune escape
Anton A, Hutchinson R, Hovens C, Christie M, Ryan A, Gibbs P, et al.
PLoS One
. 2024 Nov;
19(11):e0301943.
PMID: 39602457
Background: Immunotherapy has demonstrated limited activity in prostate cancer to date. This likely reflects an immune suppressive tumor microenvironment (TME), with previous studies suggesting low PD-L1 expression and a sparse...
5.
Lee S, Le K, Christie M, Dunne B, Herath D, McCusker M
Radiol Case Rep
. 2024 Aug;
19(9):4029-4033.
PMID: 39091341
Pseudoprogression of malignancy in patients treated with systemic immunotherapy is a well- recognised phenomenon and has also been seen in patients treated with combined chemoimmunotherapy. Neoadjuvant chemoimmunotherapy prior to surgery...
6.
Christie M, Haeri Mazanderani A, Sherman G, Feucht U
South Afr J HIV Med
. 2024 Jun;
25(1):1557.
PMID: 38840712
Background: The coronavirus disease 2019 (COVID-19) pandemic disrupted paediatric HIV services across South Africa. Shortly before COVID-19, updated national HIV guidelines were released. Objectives: This study describes COVID-19's impact on...
7.
Galea L, Batrouney A, Flynn M, Christie M
Virchows Arch
. 2024 Apr;
485(5):947-952.
PMID: 38600174
Based on lineage-specific transcription factors, small-cell neuroendocrine carcinoma (SmCC) of the urinary bladder has recently been subtyped into three molecular subtypes: ASCL1, NEUROD1 and POU2F3. The latter is a master...
8.
Park Y, Plehwe W, Varatharajah K, Hale S, Christie M, Yates C
JBMR Plus
. 2024 Apr;
8(5):ziae032.
PMID: 38577522
Abbreviated Abstract: Skeletal fluorosis is rare and occurs secondary to chronic high amounts of fluoride consumption, manifesting as diffuse osteosclerosis, skeletal pain, connective tissue calcification, and increased fracture risk. We...
9.
Joyce R, Pascual R, Heitink L, Capaldo B, Vaillant F, Christie M, et al.
Nat Cell Biol
. 2024 Jan;
26(1):138-152.
PMID: 38216737
Inheritance of a BRCA2 pathogenic variant conveys a substantial life-time risk of breast cancer. Identification of the cell(s)-of-origin of BRCA2-mutant breast cancer and targetable perturbations that contribute to transformation remains...
10.
Ng J, Cai L, Girard L, Prall O, Rajan N, Khoo C, et al.
Clin Cancer Res
. 2024 Jan;
30(9):1846-1858.
PMID: 38180245
Purpose: The classification of small cell lung cancer (SCLC) into distinct molecular subtypes defined by ASCL1, NEUROD1, POU2F3, or YAP1 (SCLC-A, -N, -P, or -Y) expression, paves the way for...